P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
Brian Bressler(University of British Columbia), Dirk Demuth(Takeda (Singapore)), M Bassel, Dan J. Stein(University of Cape Town), Calum S. Neish(Takeda (Canada)), A. Greenup(St. Paul's Hospital), Manmohan Soni(EVRAZ (United Kingdom)), J M Khalid(Takeda (United Kingdom)), Gabriela Radulescu(Smithsonian Institution)
Cited by 4
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Posttraumatic stress disorder in the World Mental Health Surveys
|Psychological Medicine|2017|1.4k
Barriers to mental health treatment: results from the WHO World Mental Health surveys
|Psychological Medicine|2013|1.3k
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
Age of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries
|The Lancet Psychiatry|2023|565